You are here: Industry Insights > Pfizer

News List

BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute l worldpharmanews
July 13, 2017
Pfizer Inc. (NYSE:PFE) announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
The curious case of Mylotarg: Pfizer’s leukaemia drug set to return pharmaphorum
July 13, 2017
Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia.
Pfizer facing NICE showdown over leukaemia drug pharmaphorum
July 05, 2017
Pfizer’s Besponsa leukaemia drug has been approved in Europe, but the company is heading for a showdown with England’s NICE, which has said in a draft decision that the medicine it is too expensive for regular NHS funding.
New Pfizer EU approval offers first treatment option for leukaemia subtype pharmafile
July 04, 2017
Pfizer has revealed that its drug Besponsa (inotuzumab ozogamicin) has received approval from the European Commission as a monotherapy...
Pfizer starts construction of new R&D facility in Missouri, US pharmaceutical-technology
July 03, 2017
US-based biopharmaceutical company Pfizer has begun construction of its latest and advanced research and development (R&D) and process development facility in the country.
Pfizer breaks ground on new R&D facility in Chesterfield, Missouri worldpharmanews
June 30, 2017
Pfizer Inc., (NYSE:PFE) one of the world's premier biopharmaceutical companies, broke ground on a state-of-the art Research and Development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield, MO.
Pfizer’s biosimilar gets another FDA rejection biospectrumasia
June 28, 2017
FDA complete response letter (CRL) cited concerns about the same Pfizer fill-finish plant whose problems led the FDA to deny approval of a highly anticipated copy of Teva’s Copaxone that was to be finished there.
Pfizer receives expanded Health Canada approval for Ibrance in HR+, HER2- metastatic breast cancer cphi-online
June 27, 2017
New indication supported by results of Phase III PALOMA-3 Trial of Ibrance in combination with fulvestrant.
FDA updates on Pfizer drug shortages cphi-online
June 23, 2017
Pfizer says shortages caused by manufacturing, distribution and third party delays.
Pfizer and Lilly receive FDA Fast Track designation for tanezumab worldpharmanews
June 14, 2017
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chroni

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page